• 1
    Elson CO. Experimental models of intestinal inflammation: New insights into mechanisms of mucosal homeostasis. In: OgraPL, Mes-teckyJ., LammME, et al, eds. Mucosal Immunology, 2nd ed. San Diego , CA : Academic Press; 1999: 10071034.
  • 2
    Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:12031207.
  • 3
    Kundig TM, Schorle H., Bachmann MF, et al. Immune responses in interleukin-2-deficient mice. Science 1993;262:10591061.
  • 4
    Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263274.
  • 5
    Watanabe M., Ueno Y., Yajima T., et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998;187:389402.
  • 6
    Morrissey PJ, Charrier K., Braddy S., et al. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993; 178: 237244.
  • 7
    Powrie F., Mason D. Ox-22high CD4+ T cells induce wasting disease with multiple organ pathology: Prevention by the Ox-22low subset. J Exp Med 1990;172:17011708.
  • 8
    Powrie F., Leach MW, Mauze S., et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol 1993; 5: 14611471.
  • 9
    Powrie F., Leach MW, Mauze S., et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553562.
  • 10
    Powrie F., Carlino J., Leach MW, et al. A critical role for transforming growth factor-p but not interleukin 4 in the suppression of T helper type-1 mediated colitis by CD45RBlow CD4+ T cells. J Exp Med 1996; 183; 26692674.
  • 11
    Bonhagen K., Thoma S., Bland PW, et al. Cytotoxic reactivity of gut lamina propria CD4+ afj T cells in SCID mice with colitis. Eur J Immunol 1996;26:30743083.
  • 12
    Bonhagen K., Thoma S., Leithauser F., et al. A pancolitis resembling human ulcerative colitis (UC) is induced by CD4+ TCR afj T cells of athymic origin in histocompatible severe combined immunodeficient (SCID) mice. Clin Exp Immunol 1998;112:443452.
  • 13
    Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295302.
  • 14
    Takahashi T., Tagami T., Yamazaki S., et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303309.
  • 15
    Duchmann R., Kaiser I., Hermann E., et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448455.
  • 16
    Duchmann R., Schmitt E., Knolle P., et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934938.
  • 17
    Guilford WG. Idiopathic inflammatory bowel diseases. In: GuilfordWG, CenterSA, StrombeckDR, et al, eds. Strombeck's Small Animal Gastroenterology, 3rd ed. Philadelphia , PA : WB Saunders; 1996: 451486.
  • 18
    Hall EJ, Rutgers HC, Scholes SFE, et al. Histiocytic ulcerative colitis in Boxer dogs in the UK. J Small Anim Pract 1994;35:509515.
  • 19
    Breitschwerdt EB, Waltman C., Hagstad HV, et al. Clinical and epidemiologic characterization of a diarrheal syndrome in Basenji dogs. J Am Vet Med Assoc 1982;180:914920.
  • 20
    Breitschwerdt EB, Ochoa R., Barta M., et al. Clinical and laboratory characterization of Basenji dogs with immuno-proliferative small intestinal disease. Am J Vet Res 1984;45:267273.
  • 21
    MacLachlan NJ, Breitschwerdt EB, Chambers JM, et al. Gastroenteritis of Basenji dogs. Vet Pathol 1988;25:3641.
  • 22
    Breitschwerdt EB, Halliwell WH, Foley CW, et al. An hereditary diarrhetic syndrome in the Basenji characterized by malabsorption, protein-losing enteropathy and hypergammaglobulinemia. J Am Anim Hosp Assoc 1980;16:551560.
  • 23
    Breitschwerdt EB. Immunoproliferative enteropathy of Basen-jis. Semin Vet Med Surg Small Anim 1992;7:153161.
  • 24
    Flesja K., Yri T. Protein-losing enteropathy in the Lundehund. J Small Anim Pract 1977;18:1123.
  • 25
    Littman MP, Giger U. Familial protein-losing enteropathy (PLE) and/or protein-losing nephropathy (PLN) in Soft-Coated Wheaten Terriers (SCWT). J Vet Intern Med 1990;4:133.
  • 26
    Vaden SL, Hammerberg B., Davenport DJ, et al. Food hyper-sensitivity reactions in Soft Coated Wheaten Terriers with protein-losing enteropathy or protein-losing nephropathy or both: Gastroscopic food sensitivity testing, dietary provocation, and fecal immunoglobulin E. J Vet Intern Med 2000;14:6067.
  • 27
    Littman MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing enteropathy and protein-losing nephropathy in Soft Coated Wheaten Terriers: 222 cases (1983–1983). J Vet Intern Med 2000; 14: 6880.
  • 28
    Vaden SL, Sellon RK, Melgarejo LT, et al. Evaluation of intestinal permeability and gluten sensitivity in Soft-Coated Wheaten Terriers with familial protein-losing enteropathy, protein-losing nephrop-athy, or both. Am J Vet Res 2000;61:518524.
  • 29
    Barkin R., Lewis JH. Overview on inflammatory bowel disease in humans. Semin Vet Med Surg 1992;7:117127.
  • 30
    Morson BC, Dawson IMP. The small intestine. In: SymmsWSC, ed. Systemic Pathology. Vol 3. Alimentary System. Edinburgh : Churchill Livingstone; 1978: 10541098.
  • 31
    Fiocchi C. Inflammatory bowel disease: Etiology and patho-genesis. Gastroenterology 1998;115:182205.
  • 32
    Karp LC, Targan SR. Ulcerative colitis: Evidence for an updated hypothesis of disease pathogenesis. In: OgraPL, MesteckyJ., LammME, et al, eds. Mucosal Immunology, 2nd ed. San Diego , CA : Academic Press; 1999: 10471053.
  • 33
    Duchmann R., Zeitz M. Crohn's disease. In: OgraPL, MesteckyJ., LammME, et al, eds. Mucosal Immunology, 2nd ed. San Diego , CA : Academic Press; 1999: 10551080.
  • 34
    Hugot JP, Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599603.
  • 35
    Ogura Y., Bonen DK, Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603606.
  • 36
    Jergens AE. Inflammatory bowel disease–Current perspectives. Vet Clin North Am 1999;29:501521.
  • 37
    Jergens AE, Moore FM, Kaiser MS, et al. Morphometric evaluation of immunoglobulin A–containing and immunoglobulin G–con-taining cells and T cells in duodenal mucosa from healthy dogs and from dogs with inflammatory bowel disease or non-specific gastroenteritis. Am J Vet Res 1996;57:697704.
  • 38
    Jergens AE, Gamet Y., Moore FM, et al. Colonic lymphocyte and plasma cell populations in dogs with lymphocytic-plasmacytic colitis. Am J Vet Res 1999;60:515520.
  • 39
    Stonehewer J., Simpson JW, Else RW, Macintyre N. Evaluation of B and T lymphocytes and plasma cells in colonic mucosa from healthy dogs and from dogs with inflammatory bowel disease. Res Vet Sci 1998;65:5963.
  • 40
    German AJ, Hall EJ, Day MJ. Immune cell populations within the duodenal mucosa of dogs with enteropathies. J Vet Intern Med 2001;15:1425.
  • 41
    Locher C., Tipold A., Welle M., et al. Quantitative assessment of mast cells and expression of IgE protein and mRNA for IgE and in-terleukin 4 in the gastrointestinal tract of healthy dogs and dogs with inflammatory bowel disease. Am J Vet Res 2001;62:211216.
  • 42
    Knutson L., Ahrenstedt O., Odlind B., Hallgren R. The jejunal secretion of histamine is increased in active Crohn's disease. Gastro-enterology 1990;98:849854.
  • 43
    Jergens AE, Sonea IM, Kaufman LK, et al. Flow cytometric analysis of mucosal lymphocytes in dogs with inflammatory bowel disease. J Vet Intern Med 2001;15:275.
  • 44
    Jergens AE, Schreiner CA, Ahrens FA, et al. Laboratory assessment of disease activity in canine inflammatory bowel disease. J Vet Intern Med 2000;14:347.
  • 45
    Gunawardana SC, Jergens AE, Ahrens FA, Niyo Y. Colonic nitrite and immunoglobulin G concentrations in dogs with inflammatory bowel disease. J Am Vet Med Assoc 1997;211:318321.
  • 46
    Jergens AE, Carpenter SL, Wannemuehler Y., Ahrens FA. Molecular detection of inducible nitric oxide synthase in canine inflammatory bowel disease. J Vet Intern Med 1998;12:205.
  • 47
    German AJ, Helps CR, Hall EJ, Day MJ. Cytokine mRNA expression in mucosal biopsies from German Shepherd Dogs with small intestinal enteropathies. Digest Dis Sci 2000;45:717.
  • 48
    Ridyard AE, Nuttall TJ, Else RW, et al. Cytokine mRNA expression in the colonic mucosa of dogs with idiopathic colitis. Proceedings of the European Society for Veterinary Internal Medicine Congress, Dublin, Ireland, 2001: 5455.
  • 49
    Schleuren M., Dais W., Steinhilber D., et al. Effects of long-term application of fish oil on patients with Crohn's disease. Scand J Gas-trenterol 1989;24(Suppl 158):100101.
  • 50
    Van Kruiningen HJ, Montali RJ, Strandberg JD, Kirk RW. A granulomatous colitis of dogs with histological resemblance to Whip-ple's disease. Pathol Vet 1965;2:521544.
  • 51
    Stokes JE, Kruger JM, Mullaney T., et al. Histiocytic ulcerative colitis in three non-Boxer dogs. J Am Anim Hosp Assoc 2001;37:461465.
  • 52
    Kennedy PC, Cello RM. Colitis of Boxer dogs. Gastroenterol-ogy 1966;51:926931.
  • 53
    Sander CH, Langham RF. Canine histiocytic ulcerative colitis. A condition resembling Whipple's disease, colonic histiocytosis, and malakoplakia in man. Arch Pathol 1968; 85: 94100.
  • 54
    Russell SW, Gomez JA, Trowbridge JO. Canine histiocytic ul-cerative colitis. The early lesion and its progression to ulceration. Lab Invest 1971; 25: 509515.
  • 55
    Lindberg R., Segall T. Histiocytic ulcerative colitis in a Boxer. A case report. Nord Veterinaermed 1977; 29: 552555.
  • 56
    Hill FWG, Sullivan ND. Histiocytic ulcerative colitis in a Boxer dog. Aust Vet J 1978;54:447449.
  • 57
    Churcher RK, Watson ADJ. Canine histiocytic ulcerative colitis. Aust Vet J 1997;75:710713.
  • 58
    Van Kruiningen HJ. Granulomatous colitis of Boxer dogs: Comparative aspects. Gastroenterology 1967;53:114122.
  • 59
    Van Kruiningen HJ. The ultrastructure of macrophages in gran-ulomatous colitis of Boxer dogs. Vet Pathol 1975;12:446459.
  • 60
    Cockrell BY, Krehbiel JD. Ultrastructural changes in histiocytic ulcerative colitis in a Boxer. Am J Vet Res 1972;33:453459.
  • 61
    Bowe PS, Van Kruiningen HJ, Rosendal S. Attempts to produce granulomatous colitis in Boxer dogs with a mycoplasm. Can J Comp Med 1982;46:430433.
  • 62
    Gomez JA, Russell SW, Trowbridge JO, Lee J. Canine histio-cytic ulcerative colitis–An ultrastructural study of the early mucosal lesion. Digest Dis 1977;22:485496.
  • 63
    German AJ, Hall EJ, Kelly DF, et al. An immunohistochemical study of histiocytic ulcerative colitis in Boxer dogs. J Comp Pathol 2000;122:163175.
  • 64
    Helgeland L., Tysk C., Jarnerot G., et al. IgG subclass distribution in serum and rectal mucosa of monozygotic twins with or without inflammatory bowel disease. Gut 1992;33:13581364.
  • 65
    Ruthlein J., Ibe M., Burghardt W., et al. Immunoglobulin-G (IgG), IgG1, and IgG2 determinations from endoscopic biopsy specimens in control, Crohn's disease and ulcerative colitis subjects. Gut 1992;33:507512.
  • 66
    Arato A., Savilahti E. IgG3 and IgG4 cells are increased in active ulcerative colitis. Digestion 1990;47:3541.
  • 67
    Mayer L., Eisenhardt D., Solomon P., et al. Expression of class II molecules on intestinal epithelial cells in humans–Differences between normal and inflammatory bowel disease. Gastroenterology 1991;100:312.
  • 68
    Bland PW, Warren LG. Antigen presentation by epithelial cells of the rat small intestine. I. Kinetics, antigen specificity and blocking by anti-Ia antisera. Immunology 1986; 58: 17.
  • 69
    Fox IW, Hoag WG, Strout J. Breed susceptibility, pathogenicity and epidemiology of endemic coliform enteritis in the dog. Lab Anim Care 1965;15:194200.
  • 70
    de Buysscher EV, Breitschwerdt EB, MacLachlan NJ. Elevated serum IgA associated with immunoproliferative enteropathy of Basenji dogs: Lack of evidence for alpha-heavy-chain disease or enhanced intestinal IgA secretion. Vet Immunol Immunopathol 1988;20:4152.
  • 71
    Ochoa R., Breitschwerdt EB, Lincoln KL. Immunoproliferative small intestinal disease in Basenji dogs: Morphologic implications. Am J Vet Res 1984;45:482490.
  • 72
    Barta O., Breitschwerdt EB, Shaffer LM, Pourciau SS. Lymphocyte transformation and humoral immune factors in Basenji dogs with immunoproliferative small intestinal disease. Am J Vet Res 1983; 44:19541959.
  • 73
    Breitschwerdt EB, Hirakawa DA, Hurlbert SA, et al. Effects of dietary protein source on Basenjis with immunproliferative enteropa-thy. Am J Vet Res 1992;53:234236.
  • 74
    Yamasaki K., Suematsu H., Takahashi T. Comparison of gastric and duodenal lesions in dogs and cats with and without lymphocytic-plasmacytic enteritis. J Am Vet Med Assoc 1996;209:9597.
  • 75
    German AJ, Hall EJ, Day MJ. Analysis of leucocyte subsets in the canine intestine. J Comp Pathol 1999;120:129145.
  • 76
    Batt RM, Carter MW, McLean L. Morphological and biochemical studies of a naturally occurring enteropathy in the Irish Setter dog: A comparison with coeliac disease in man. Res Vet Sci 1984;37:339346.
  • 77
    Batt RM, Carter MW, McLean L. Wheat-sensitive enteropathy in Irish Setter dogs: Possible age-related brush border abnormalities. Res Vet Sci 1985;39:8083.
  • 78
    Batt RM, McLean L., Carter MW. Sequential morphological and biochemical studies of naturally occurring wheat-sensitive enteropathy in Irish Setter dogs. Digest Dis Sci 1987;32:184194.
  • 79
    Hall EJ, Batt RM. Development of wheat-sensitive enteropathy in Irish Setters: Morphologic changes. Am J Vet Res 1990;51:978982.
  • 80
    Garden OA, Pidduck H., Lakhani KH, et al. Inheritance of glu-ten-sensititive enteropathy in Irish Setters. Am J Vet Res 2000;61:462468.
  • 81
    Polvi A., Garden OA, Houlston RS, et al. Genetic susceptibility to gluten sensitive enteropathy in Irish Setter dogs is not linked to the major histocompatibility complex. Tissue Antigens 1998;52:543549.
  • 82
    Elwood CM, Moore PF, Batt RM. Expression of gluten sensitive enteropathy (GSE) of Irish Setter dogs may be age dependent. J Vet Intern Med 2001;15:274.
  • 83
    Hall EJ, Batt RM. Abnormal permeability precedes the development of a gluten sensitive enteropathy in Irish Setter dogs. Gut 1991; 32; 749753.
  • 84
    Elwood CM, Garden OA, Manners HK, et al. Altered populations of T-lymphocytes in the jejunal mucosa of Irish Setter dogs with gluten sensitive enteropathy. Gastroenterology 1996;110:A903.
  • 85
    Elwood CM, Garden OA, Hamblin AS, Batt RM. Gluten challenge in Irish Setters with gluten sensitive enteropathy (GSE): Peripheral leucocyte responses. Proceedings of the European Society for Veterinary Internal Medicine Congress, Lyon, France, 1997: 157.
  • 86
    Elwood CM, Garden OA, Hamblin AS, et al. Mucosal and systemic cell mediated immune responses to gluten in Irish Setters with gluten sensitive enteropathy. Gastroenterology 1998;114:G3985.
  • 87
    Hall EJ, Carter SD, Barnes A., Batt RM. Immune responses to dietary antigens in gluten-sensitive enteropathy of Irish Setters. Res Vet Sci 1992;53:293299.
  • 88
    Hall EJ, Simpson KW. Diseases of the small intestine. In: EttingerSJ, FeldmanEC, eds. Textbook of Veterinary Internal Medicine, 5th ed. Philadelphia , PA : WB Saunders; 2000: 11821237.
  • 89
    Batt RM, Needham JR, Carter MW. Bacterial overgrowth associated with a naturally occurring enteropathy in the German Shepherd Dog. Res Vet Sci 1983;35:4246.
  • 90
    Whitbread TJ, Batt RM, Garthwaite G. Relative deficiency of serum IgA in the German Shepherd Dog: A breed abnormality. Res Vet Sci 1984;37:350352.
  • 91
    Batt RM, Barnes A., Rutgers HC, Carter SC. Relative IgA deficiency and small intestinal bacterial overgrowth in German Shepherd Dogs. Res Vet Sci 1991;50:106111.
  • 92
    Day MJ, Penhale WJ. Serum immunoglobulin A determination in normal and diseased dogs. Res Vet Sci 1988;45:360363.
  • 93
    German AJ, Hall EJ, Day MJ. Relative deficiency in IgA production by duodenal explants from German Shepherd Dogs with small intestinal disease. Vet Immunol Immunopathol 2000;76:2543.
  • 94
    Day MJ. Low IgA concentrations in the tears of German Shepherd Dogs. Aust Vet J 1996;74:433434.
  • 95
    Littler RM, Garden OA, Batt RM. Immunoglobulin concentrations in faecal extracts as a measure of canine mucosal immune function. Proceedings of the British Small Animal Veterinary Association Congress, Birmingham, UK, April 1999: 278.
  • 96
    Willard MD, Simpson RB, Delles EK, et al. Effect of dietary supplementation of fructo-oligosaccharides on small intestinal bacterial overgrowth in dogs. Am J Vet Res 1994;55:654659.
  • 97
    Willard MD, Simpson RB, Fossum W., et al. Characterization of naturally developing small intestinal bacterial overgrowth in 16 German Shepherd Dogs. J Am Vet Med Assoc 1994;204:12011206.
  • 98
    Littler RM, Batt RM, Lloyd DH. Low mucosal IgA is associated with colonisation by gut enteropathogenic E coli in the GSD. Proceedings of the British Small Animal Veterinary Association Congress, Birmingham, UK, 2000: 277.
  • 99
    Garden OA, Elwood CM, Desport M., Batt RM. In situ hybridization as a technique for the immunological investigation of canine intestine: Jejunal expression of IFN-7 and IL-10 in Irish Setters and Beagles. Vet Immunol Immunopathol 1999;70:117.
  • 100
    Batt RM, McLean L., Riley JE. Response of the jejunal mucosa of dogs with aerobic and anaerobic bacterial overgrowth to antibiotic therapy. Gut 1988;29:473482.
  • 101
    Brandwein SL, McCabe RP, Cong YZ, et al. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997;159:4452.
  • 102
    Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:1401414019.
  • 103
    Attur MG, Patel RN, Patel PD, et al. Tetracycline upregulates COX-2 expression and prostaglandin E2 production independent of its effects on nitric oxide. J Immunol 1999;162:31603167.
  • 105
    Patel RN, Attur MG, Dave MN, et al. A novel mechanism of action of chemically modified tetracyclines: Inhibition of COX-2-me-diated prostaglandin E2 production. J Immunol 1999;163:34593467.
  • 105
    Batt RM, Carter MW, Peters TJ. Biochemical changes in the jejunal mucosa of dogs with a naturally occurring enteropathy associated with bacterial overgrowth. Gut 1984;25:816823.
  • 106
    Batt RM, McLean L. Comparison of the biochemical changes in the jejunal mucosa of dogs with aerobic and anaerobic bacterial overgrowth. Gastroenterology 1988;93:986993.
  • 107
    Hall EJ, Batt RM. Enhanced intestinal permeability to 51Cr-labeled EDTA in dogs with small intestinal disease. J Am Vet Med Assoc 1990;196:9195.
  • 108
    Hart CA, Embaye H., Getty B., et al. Ultrastructural lesions to the canine intestinal epithelium caused by enteropathogenic E coli. J Small Anim Pract 1990; 31: 591594.
  • 109
    Hart CA, Batt RM, Saunders JR. Diarrhoea caused by Escherichia coli. Ann Trop Paediatr 1993; 13: 121131.
  • 110
    Batt RM, Rutgers HC, Sancak AA. Enteric bacteria: Friend or foe J Small Anim Pract 1996;37:261267.
  • 111
    Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. II. Induction of specific al-loantigen unresponsiveness mediated by a nylon wool adherent suppressor cell. J Immunol 1981; 126: 961968.
  • 112
    Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primered lymphocytes to TCGF. J Immunol 1982; 128: 355359.
  • 113
    Hess AD, Donnenberg AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human lymphocyte responses in vitro. V. Analysis of responding T lymphocyte subpopulations in primary MLR with monoclonal antibodies. J Immunol 1983; 130: 717721.
  • 114
    Converse PJ, Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporine on the response of normal human lymphocytes to cyto-megalovirus in vitro. Infect Immun 1983;41:12261233.
  • 115
    Schreiber SL, Crabtree CR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136142.
  • 116
    Ardizzone S., Porro GB. A pratical guide to the management of distal ulcerative colitis. Drugs 1998;55:519542.
  • 117
    Lichtiger S., Present DH, Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:18411845.
  • 118
    Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:14291435.
  • 119
    Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:4863.
  • 120
    Fernandez-Banares F., Bertran X., Esteve-Comas M., et al. Aza-thioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:24982499.
  • 121
    Florin THJ, Roberts RK, Watson MR, Radford-Smith GL. Treatment of steroid-refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust NZ J Med 1998;28:344345.
  • 122
    Neurath MF, Wanitschke R., Peters M., et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625628.
  • 123
    Present DH. Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease Gut 1999;44:592593.
  • 124
    Radford-Smith GL, Taylor P., Florin THJ. Mycophenolate mo-fetil in IBD patients. Lancet 1999;354:13861387.
  • 125
    Orth T., Peters M., Schkaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: A 12-month pilot study. Am J Gastroenterol 2000;95:12011207.
    Direct Link:
  • 126
    Fellermann K., Steffen M., Stein J., et al. Mycophenolate mo-fetil: Lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:171176.
  • 127
    Moreira AL, Sampaio EP, Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:16751680.
  • 128
    Moller DR, Wysocka M., Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:51575161.
  • 129
    Meierhofer C., Dunzendorfer S., Wiedermann CJ. Protein ki-nase C-dependent effects on leukocyte migration of thalidomide. J Infect Dis 1999;180:216219.
  • 130
    D'Amato RJ, Loughnan MS, Flynn E., Folkman J. Thalido-mide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:40824085.
  • 131
    Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology 1999;117:12711277.
  • 132
    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:12781287.
  • 133
    Bessler H., Gilgal R., Djaldetti M., Zahavi I. Effects of pent-oxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 1986;40:747754.
  • 134
    Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142:12741280.
  • 135
    Reimund JM, Dumont S., Muller CD, et al. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475480.
  • 136
    Bauditz J., Haemling J., Ortner M., et al. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470474.
  • 137
    D'Haens G., Van Deventer S., Van Hogezand R., et al. Endoscopic and histological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:10291034.
  • 138
    Baert FJ, D'Haens GR, Peeters M., et al. Tumor necrosis factor a antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:2228.
  • 139
    Stronkhorst A., Radema S., Yong SL, et al. CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study. Gut 1997;40:320327.
  • 140
    Lehrer SB, Horner WE, Reese G. Why are some proteins allergenic? Implications for biotechnology. Crit Rev Food Sci Nutr 1996;36:553564.
  • 141
    Davis PJ, Williams SC. Protein modification by thermal processing. Allergy 1998;53(Suppl 46):102105.
  • 142
    Hannah SS, Laflamme DP, Marks SL. Hydrolyzed proteins in diets for the management of food hypersensitivity or inflammatory bowel disease. Proceedings of the WSAVA/FECAVA World Congress, Amsterdam, 2000: 517.
  • 143
    Horrobin DF. Medical uses of essential fatty acid (EFAs). Vet Dermatol 1993;4:161166.
  • 144
    Kremer JM, Lawrence DA, Jubiz W., et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990; 33: 810820.
  • 145
    Stenson WF, Cort D., Rodgers J., et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992;116:609614.
  • 146
    O'Moran CA. Nutritional therapy in ambulatory patients. Digest Dis Sci 1987;32(Suppl):9599.
  • 147
    Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12-month randomized controlled trial. Gut 1992;33:922928.
  • 148
    Campieri M., Gionchetti P. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative Gastroenterology 1999;116:12461249.
  • 149
    Wagner RD, Warner T., Roberts L., et al. Colonization of con-genitally immunodeficient mice with probiotic bacteria. Infect Immun 1997;65:33453351.
  • 150
    Hessle C., Hanson LA, Wold AE. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 1999;116:276282.
  • 151
    Bircher J., Muller J., Guggenheim P. Treatment of chronic porto-systemic encephalopathy with lactulose (1–4 betagalactosidofruc-tose). Lancet 1966;108:890893.
  • 152
    Meijer HP, Welters CFM, Heineman E., et al. Effect of enteral inulin on the pouch disease activity index and on epithelial gene expression within the ileoanal pouch: A randomized, placebo-controlled crossover study. Gastroenterology 1998; 114: G1618 (abstract).
  • 153
    Bailey JS, Blankenship LC, Cox NA. Effect of fructooligo-saccharide on Salmonella colonization of the chicken intestine. Poult Sci 1991; 70; 24332438.
  • 154
    Brown DH. Applications of fructooligosaccharides in human health. In: CareyDP, NortonSA, BolserSM, eds. Recent Advances in Canine and Feline Nutritional Research: Proceedings of the Iams International Nutrition Symposium, 1996: 4144.
  • 155
    Sparkes AH, Papasouliotis K., Sunvold G., et al. Bacterial flora in the duodenum of healthy cats, and effect of dietary supplementation with fructo-oligosaccharides. Am J Vet Res 1998;59:431435.
  • 156
    Videla S., Vilaseca J., Garcia-Lafuente A., et al. Dietary inulin prevents distal colitis induced by dextran sulfate sodium (DSS). Gas-troenterology 1998; 114: G4541 (abstract).
  • 157
    Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:11071114.